breast cancer

[Cell Death & Disease] The authors identified MINDY1, a member belongs to the motif interacting with Ubcontaining novel DUB family (MINDY), as a potential deubiquitylase of estrogen receptor α in breast cancer.

[Cancer Gene Therapy] Investigators conducted a qRT-PCR assay to measure the expression of downregulated RNA in cancer (DRAIC) and other downstream target genes. They uncovered that DRAIC was expressed at a high level in breast cancer cells.

[Bioscience Reports] Scientists investigated the effects of sauchinone on the growth of breast cancer cells along with the underlying molecular mechanisms. Their results showed that sauchinone treatment markedly inhibited the proliferation, migration, and invasion of breast cancer cells.

[Precirix NV] Precirix NV announced that it has dosed the first patients in its Phase I/II clinical study of CAM-H2 for the treatment of HER2-positive metastatic cancer. The trial will evaluate safety, tumor uptake, tumor retention and early signs of antitumor activity of single-agent CAM-H2 in HER2-positive metastatic breast and gastric/gastro-esophageal cancer patients.

[Science Advances] The authors designed PEGylated lipid nanoparticles loaded with a non-opioid analgesic, bupivacaine, to target neurons within breast cancer tumors and suppress nerve-to-cancer cross-talk.

[Oncogene] Scientists identified RNA Binding Motif Single Stranded Interacting Protein 3 (RBMS3) as a novel and common effector of epithelial-to-mesenchymal transition (EMT), which could be a promising therapeutic target for triple-negative breast cancer treatment.